Loading…
Reported covered position: Health Policy Advisor, Senior Health Policy Advisor, Health Policy Director, Deputy Chief of Staff & Senior Advisor, Chief if Staff, Chieft of Staff and Senior Policy Advisor, Director Policy and Researvch, Policy Director, House of Representatives.
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
HIV/AIDS testing and treatment, technology transfer and patent rights and funding, patent reform legislation. Patient Protection and Affordable Care Act implementation. Issues related to access to pharmaceuticals and intellectual property protection. Intellectual property reform. S.1137 - PATENT Act & HR. 9 - Innovation Act
HIV/AIDS testing and treatment, technology transfer and patent rights and funding, patent reform legislation. Patient Protection and Affordable Care Act implementation. Issues related to access to pharmaceuticals and intellectual property protection. Intellectual property reform. S.1137 - PATENT Act & HR. 9 - Innovation Act
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
GILEAD SCIENCES INC via GILEAD SCIENCES, INC.
2016 · first_quarter · Q1
HIV/AIDS testing and treatment, technology transfer and patent rights and funding, patent reform legislation. Patient Protection and Affordable Care Act implementation. Issues related to access to pharmaceuticals and intellectual property protection. Intellectual property reform. S.1137 - PATENT Act & HR. 9 - Innovation Act
Appropriations; education related to Hepatitis C treatment guidelines and funding issues. Issues related to coverage, access and reimbursement of pharmaceuticals for veterans. Education related to Implementation of Veterans Access to Care Act, HR 4810/3230 and PL 113-146.
Source: Senate LDA
Pending healthcare legislation and potential impact on the biopharmaceutical industry; Ryan White Care Act reauthorization; Hepatitis C policy; PEPFAR reauthorization; HIV/AIDS research, testing, and treatment; Affordable Care Act implementation; HCV screening and linkage to care programs; House Committee on Energy and Commerce 21st Century Cures initiative. Funding for HCV and public health activities via appropriations. Pharmaceutical policy as it relates to payments under the 340B program. S.1287 - Viral Hepatitis Testing Act of 2015. Prison population and hepatitis C.
Veteran Access to Care Act of 2014
Client: GILEAD SCIENCES INC · Firm: GILEAD SCIENCES, INC.
Appropriations; education related to Hepatitis C treatment guidelines and funding issues. Issues related to coverage, access and reimbursement of pharmaceuticals for veterans. Education related to Implementation of Veterans Access to Care Act, HR 4810/3230 and PL 113-146.
U.S.-Israel Security Cooperation Act
Client: GILEAD SCIENCES INC · Firm: GILEAD SCIENCES, INC.
Appropriations; education related to Hepatitis C. Access to Care Act, HR 4810. Issues related to coverage, access and reimbursement of pharmaceuticals for veterans.
U.S.-Israel Security Cooperation Act
Client: GILEAD SCIENCES INC · Firm: GILEAD SCIENCES, INC.
Appropriations; education related to Hepatitis C. Access to Care Act, HR 4810. Issues related to coverage, access and reimbursement of pharmaceuticals for veterans.
HIV/AIDS testing and treatment, technology transfer and patent rights and funding, patent reform legislation. Patient Protection and Affordable Care Act implementation. Issues related to access to pharmaceuticals and intellectual property protection. Intellectual property reform. S.1137 - PATENT Act & HR. 9 - Innovation Act
HIV/AIDS testing and treatment, technology transfer and patent rights and funding, patent reform legislation. Patient Protection and Affordable Care Act implementation. Issues related to access to pharmaceuticals and intellectual property protection. Intellectual property reform. S.1137 - PATENT Act & HR. 9 - Innovation Act
Pending healthcare legislation and potential impact on the biopharmaceutical industry; Ryan White Care Act reauthorization; Hepatitis C policy; PEPFAR reauthorization; HIV/AIDS research, testing, and treatment; Affordable Care Act implementation; HCV screening and linkage to care programs; House Committee on Energy and Commerce 21st Century Cures initiative. Funding for HCV and public health activities via appropriations. Pharmaceutical policy as it relates to payments under the 340B program. S.1287 - Viral Hepatitis Testing Act of 2015.
Veteran Access to Care Act of 2014
Client: GILEAD SCIENCES INC · Firm: GILEAD SCIENCES, INC.
Appropriations; education related to Hepatitis C treatment guidelines and funding issues. Issues related to coverage, access and reimbursement of pharmaceuticals for veterans. Education related to Implementation of Veterans Access to Care Act, HR 4810/3230 and PL 113-146.
Coverage of pharmaceuticals, cost-sharing and other access issues; 21st Century Cures initiative; Implementation of Public Law No: 111-148, the Patient Protection and Affordable Care Act; Issues related to coverage and reimbursement of pharmaceuticals; Issues related to Medicare, Medicaid and Affordable Care Act implementation; and FDA issues and 340B.
Ryan White Care Act reauthorization; Hepatitis C (HCV) policy; PEPFAR reauthorization; HIV/AIDS research, testing, and treatment; Affordable Care Act implementation; HCV testing, screening and linkage to care programs; House Committee on Energy and Commerce 21st Century Cures initiative. Federal program coverage; access and reimbursement issues for Hepatitis C, HIV, and oncology products. Coverage of pharmaceuticals, cost-sharing and other access issues; Implementation of Public Law No: 111-148; issues related to coverage and reimbursement of pharmaceuticals; FDA issues and 340B.
Pending healthcare legislation and potential impact on the biopharmaceutical industry; Ryan White Care Act reauthorization; Hepatitis C policy; PEPFAR reauthorization; HIV/AIDS research, testing, and treatment; Affordable Care Act implementation; HCV screening and linkage to care programs; House Committee on Energy and Commerce 21st Century Cures initiative. Funding for HCV and public health activities via appropriations. Pharmaceutical policy as it relates to payments under the 340B program. S.1287 - Viral Hepatitis Testing Act of 2015. Prison population and hepatitis C.
Issues related to access to pharmaceuticals, international finance for health services and intellectual property protection.
Issues related to healthcare funding and cost-savings.
Issues related to pharmaceutical innovation and intellectual property protection.
Education related to HCV issues.
Filing targets: Commerce, Dept of (DOC), Defense, Dept of (DOD), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), Veterans Affairs, Dept of (VA)
GILEAD SCIENCES INC via GILEAD SCIENCES, INC.
2015 · fourth_quarter · Q4
Issues related to pharmaceutical innovation and intellectual property protection.
HIV/AIDS testing and treatment, technology transfer and patent rights and funding, patent reform legislation. Patient Protection and Affordable Care Act implementation. Issues related to access to pharmaceuticals and intellectual property protection. Intellectual property reform. S.1137 - PATENT Act & HR. 9 - Innovation Act
Appropriations; education related to Hepatitis C treatment guidelines and funding issues. Issues related to coverage, access and reimbursement of pharmaceuticals for veterans. Education related to Implementation of Veterans Access to Care Act, HR 4810/3230 and PL 113-146.
Issues related to access to pharmaceuticals, international finance for health services and intellectual property protection.
Issues related to healthcare funding and cost-savings.
Education related to HCV issues.
Coverage of pharmaceuticals, cost-sharing and other access issues; 21st Century Cures initiative; Implementation of Public Law No: 111-148, the Patient Protection and Affordable Care Act; Issues related to coverage and reimbursement of pharmaceuticals; Issues related to Medicare, Medicaid and Affordable Care Act implementation; and FDA issues and 340B.
Pending healthcare legislation and potential impact on the biopharmaceutical industry; Ryan White Care Act reauthorization; Hepatitis C policy; PEPFAR reauthorization; HIV/AIDS research, testing, and treatment; Affordable Care Act implementation; HCV screening and linkage to care programs; House Committee on Energy and Commerce 21st Century Cures initiative. Funding for HCV and public health activities via appropriations. Pharmaceutical policy as it relates to payments under the 340B program. S.1287 - Viral Hepatitis Testing Act of 2015.
Ryan White Care Act reauthorization; Hepatitis C (HCV) policy; PEPFAR reauthorization; HIV/AIDS research, testing, and treatment; Affordable Care Act implementation; HCV testing, screening and linkage to care programs; House Committee on Energy and Commerce 21st Century Cures initiative. Federal program coverage; access and reimbursement issues for Hepatitis C, HIV, and oncology products. Coverage of pharmaceuticals, cost-sharing and other access issues; Implementation of Public Law No: 111-148; issues related to coverage and reimbursement of pharmaceuticals; FDA issues and 340B.
Filing targets: Commerce, Dept of (DOC), Defense, Dept of (DOD), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), Veterans Affairs, Dept of (VA)
GILEAD SCIENCES INC via GILEAD SCIENCES, INC.
2015 · third_quarter · Q3
Issues related to access to pharmaceuticals, international finance for health services and intellectual property protection.
Issues related to pharmaceutical innovation and intellectual property protection.
Appropriations; education related to Hepatitis C. Access to Care Act, HR 4810. Issues related to coverage, access and reimbursement of pharmaceuticals for veterans.
Education related to HCV issues.
Issues related to healthcare funding and cost-savings.
Specific lobbying issues: HIV/AIDS testing and treatment, technology transfer and patent rights and funding, patent reform legislation. Patient Protection and Affordable Care Act implementation.Issues related to access to pharmaceuticals and intellectual property protection.
Coverage of pharmaceuticals, cost-sharing and other access issues; 21st Century Cures initiative; Implementation of Public Law No: 111-148, the Patient Protection and Affordable Care Act; Issues related to coverage and reimbursement of pharmaceuticals; Issues related to Medicare, Medicaid and Affordable Care Act implementation; and FDA issues and 340B.
Ryan White Care Act reauthorization; Hepatitis C (HCV) policy; PEPFAR reauthorization; HIV/AIDS research, testing, and treatment; Affordable Care Act implementation; HCV screening and linkage to care programs; House Committee on Energy and Commerce 21st Century Cures initiative. Federal program coverage; access and reimbursement issues for Hepatitis C, HIV, and oncology products. Viral Hepatitis Testing, Screening and treatment;HIV Testing, Research and Treatment; Coverage of pharmaceuticals, cost-sharing and other access issues; 21st Century Cures initiative; Implementation of Public Law No: 111-148, the Patient Protection and Affordable Care Act;Issues related to coverage and reimbursement of pharmaceuticals; and FDA issues and 340B.
Pending healthcare legislation and potential impact on the biopharmaceutical industry; Ryan White Care Act reauthorization; Hepatitis C policy; PEPFAR reauthorization, Ryan White Care Act reauthorization; Hepatitis C (HCV) policy; PEPFAR reauthorization; HIV/AIDS research, testing, and treatment; Affordable Care Act implementation; HCV screening and linkage to care programs; House Committee on Energy and Commerce 21st Century Cures initiative. HIV/AIDS testing and treatment, technology transfer and patent rights, and funding. Patient Protection and Affordable Care Act implementation. Hepatitis funding for screening and linkage to care programs.
Filing targets: Commerce, Dept of (DOC), Defense, Dept of (DOD), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), Veterans Affairs, Dept of (VA)
GILEAD SCIENCES INC via GILEAD SCIENCES, INC.
2015 · second_quarter · Q2
Coverage of pharmaceuticals, cost-sharing and other access issues; 21st Century Cures initiative; Implementation of Public Law No: 111-148, the Patient Protection and Affordable Care Act; Issues related to coverage and reimbursement of pharmaceuticals; Issues related to Medicare, Medicaid and Affordable Care Act implementation; and FDA issues and 340B.
Pending healthcare legislation and potential impact on the biopharmaceutical industry; Ryan White Care Act reauthorization; Hepatitis C policy; PEPFAR reauthorization, Ryan White Care Act reauthorization; Hepatitis C (HCV) policy; PEPFAR reauthorization; HIV/AIDS research, testing, and treatment; Affordable Care Act implementation; HCV screening and linkage to care programs; House Committee on Energy and Commerce 21st Century Cures initiative. HIV/AIDS testing and treatment, technology transfer and patent rights, and funding. Patient Protection and Affordable Care Act implementation. Hepatitis funding for screening and linkage to care programs.
Appropriations; education related to Hepatitis C. Access to Care Act, HR 4810. Issues related to coverage, access and reimbursement of pharmaceuticals for veterans.
Education related to HCV issues.
Issues related to access to pharmaceuticals, international finance for health services and intellectual property protection.
Specific lobbying issues: HIV/AIDS testing and treatment, technology transfer and patent rights and funding, patent reform legislation. Patient Protection and Affordable Care Act implementation.Issues related to access to pharmaceuticals and intellectual property protection.
Issues related to healthcare funding and cost-savings.
Issues related to pharmaceutical innovation and intellectual property protection.
Ryan White Care Act reauthorization; Hepatitis C (HCV) policy; PEPFAR reauthorization; HIV/AIDS research, testing, and treatment; Affordable Care Act implementation; HCV screening and linkage to care programs; House Committee on Energy and Commerce 21st Century Cures initiative. Federal program coverage; access and reimbursement issues for Hepatitis C, HIV, and oncology products. Viral Hepatitis Testing, Screening and treatment;HIV Testing, Research and Treatment; Coverage of pharmaceuticals, cost-sharing and other access issues; 21st Century Cures initiative; Implementation of Public Law No: 111-148, the Patient Protection and Affordable Care Act;Issues related to coverage and reimbursement of pharmaceuticals; and FDA issues and 340B.
Filing targets: Commerce, Dept of (DOC), Defense, Dept of (DOD), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), Veterans Affairs, Dept of (VA)
GILEAD SCIENCES INC via GILEAD SCIENCES, INC.
2015 · first_quarter · Q1
HIV/AIDS testing and treatment, technology transfer and patent rights and funding. Patient Protection and Affordable Care Act implementation.
Pending healthcare legislation and potential impact on the biopharmaceutical industry; Ryan White Care Act reauthorization; Hepatitis C policy; PEPFAR reauthorization, Ryan White Care Act reauthorization; Hepatitis C (HCV) policy; PEPFAR reauthorization; HIV/AIDS research, testing, and treatment; Affordable Care Act implementation; HCV screening and linkage to care programs; House Committee on Energy and Commerce 21st Century Cures initiative. HIV/AIDS testing and treatment, technology transfer and patent rights, and funding. Patient Protection and Affordable Care Act implementation. Hepatitis funding for screening and linkage to care programs.
Ryan White Care Act reauthorization; Hepatitis C (HCV) policy; PEPFAR reauthorization; HIV/AIDS research, testing, and treatment; Affordable Care Act implementation; HCV screening and linkage to care programs; House Committee on Energy and Commerce 21st Century Cures initiative. Federal program coverage; access and reimbursement issues for Hepatitis C, HIV, and oncology products.
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE